Over the last two decades, the price of insulin has surged as much as 1000%, placing significant burdens on companies, governments, nonprofits, and unions with self-funded health plans. Seeger Weiss Partner David Buchanan co-authored an article along with his fellow co-leads in the Insulin Pricing Litigation, outlining the key factors self-insured organizations need to consider when faced with rising medication costs. Read more here: https://lnkd.in/eUV8p_Vc
Seeger Weiss LLP’s Post
More Relevant Posts
-
NEW YORK: CALL YOUR LOCAL REPRESENTATIVES! In case you missed it, New York reached settlements totaling over $2.6 billion with companies involved in manufacturing, distributing, and selling opioids. These funds are supposed to be directed towards New York communities for treatment, recovery, and prevention efforts. SAMHSA reports over 1.5 million women suffer from Opioid Use Disorder – yet, the state of healthcare for these women is abysmal. The media and the government continue to neglect women’s needs. So it’s up to us to call our local representatives and URGE them for greater equity in the allocation of Opioid settlement monies. If you tune in to WABC New York City this Saturday, August 5th at 2:00pm, you’ll understand why I think it's absolutely necessary that a portion of these monies be allocated to women-specific treatment. “Listen to the Silence: Women Trapped in the Opioid Epidemic, Part 1” showcases several different stories with one thing in common: how our healthcare systems constantly fail women battling OUD. And then calls on each of us TO TAKE ACTION! You have the chance to not only raise your voice, but to REALLY begin to understand the levels of this epidemic and why shedding light women suffering from this disease, is imperative. I hope you take it. https://lnkd.in/esBUFX4z
Opioid settlements
ag.ny.gov
-
Sharing our new White Paper on cost implications of Leqembi for Medicare plans and risk-bearing provider systems and how Isaac Health can support: https://lnkd.in/e4ENNZAi
White Paper on cost implications of Leqembi and other anti-amyloid drugs for payers and ACOs and options for utilization management
https://www.myisaachealth.com
-
For many, the path to disease management stumbles at the pharmacy counter, where soaring medication costs can lead to non-adherence, trapping patients in a cycle of poor health and mounting debt. OptimizeRx’s DAAP transforms the patient journey – empowering HCPs and patients with real-time affordability data and financial support resources bridging the cost gap and prioritizing access Read More Now: https://lnkd.in/enxpm7Rz
Medication Access and Affordability: Impact of DAAP's Access and Adherence Module
optimizerx.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Ardelyx sues Medicare over attempt to change coverage for dialysis drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #healthcare #productmarketing
Ardelyx sues Medicare over attempt to change coverage for dialysis drug
https://endpts.com
-
The insulin price drop has caused a big shift in the pharmacy landscape. RxBenefits, Inc. Expert Bradley Nelson breaks down the complexities of the price cap and unpacks the potential financial implications for plan sponsors. Learn more: https://rxbene.fit/46LX9AJ #PBO #RxBenefits
Re-bate and Switch? Understanding All Impacts of the Insulin Price Drop
https://employers.rxbenefits.com
-
Thoughts on this? >> Ardelyx sues Medicare over attempt to change coverage for dialysis drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #healthcare #productmarketing
Ardelyx sues Medicare over attempt to change coverage for dialysis drug
https://endpts.com
-
C-Suite Pharmaceutical Executive | Gross-to-Net (GTN) Thought Leadership | Value Creator & Catalyst for Growth | Board Advisor | Building Business for Sustainable Global Impact | Founder
URGENT Press Release: Today the U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), announced the first 10 drugs covered under Medicare Part D selected for negotiation under President Biden’s Inflation Reduction Act of 2022: Eliquis Jardiance Xarelto Januvia Farxiga Entresto Enbrel Imbruvica Stelara Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill The financial impacts of this negotiation will have significant ramifications on future of these and other life sciences organizations. Start planning now for how this will impact your orgnaization’s long-term financial needs. #inflationreductionact #financialplanningandanalysis #pharmaceuticalindustry
HHS Selects the First Drugs for Medicare Drug Price Negotiation
hhs.gov
-
Major changes coming for drug pricing. Can free enterprise ideals co-exist with public health programs in an environment of rising healthcare cost with patient care on the line? Interesting that the #healthcareprovider's voice is absent.
The Top 10 List you don’t want to be on… Centers for Medicare & Medicaid Services announces its list of 10 drugs up for the first price negotiations under the Inflation Reduction Act. Read more: https://lnkd.in/enN-82Nk
Drugs from J&J, Merck, Novartis, BMS and more set for first round of Medicare price negotiations: CMS
fiercepharma.com
-
“The Increasing Access to Biosimilars Act would take a critical step toward enhancing patient access to biosimilars through the creation of a voluntary shared savings demonstration program in Medicare Part B,” said Christine Simmon, executive director of the Biosimilars Council, in a 2021 statement about the bill. “The Biosimilars Council thanks Senator Michael Bennet and Senator John Cornyn for introducing this innovative solution to encourage greater biosimilar adoption and use in the US.” If passed, the HHS Secretary will implement a 3-year demonstration project that will check if offering a special payment can encourage doctors to prescribe more biosimilars for Medicare beneficiaries. Doctors will have a choice of whether to participate, and they would be able to withdraw from the project at any time. The Secretary would also have power to remove a doctor from the project if necessary. For the doctors who choose to participate, they will receive extra payments for prescribing more biosimilars instead of originators; however, the extra payment won’t increase out-of-pocket costs for patients. After the 3 years, the Secretary will report to Congress about how well the project is functioning. Congress will then have a choice of whether to extend or expand the project.
Medication costs causing you pain? Senators Bennet (D-CO) and Cornyn (R-TX) are fighting to make lifesaving treatments more affordable with the Increasing Access to Biosimilars Act. 🚩 Click the link to understand what this bill could mean for patients https://lnkd.in/dHN5GWQr
Senators Reintroduce the Increasing Access to Biosimilars Act
centerforbiosimilars.com
-
On World Arthritis Day, we unite in our commitment to improve the lives of those facing the challenges of arthritis. Together, we can make a meaningful impact, raising awareness, and empowering those affected by arthritis. Let's stand together for a world where arthritis no longer limits possibilities. 💙 #WorldArthritisDay #ArthritisAwareness #HealthInnovation #PharmaceuticalCare #EmpoweringLives #JointHealth #SupportingWellness #ArthritisResearch #HealthcareAdvocacy #CommunitySupport #TogetherForBetterHealth"
-
NY Public Policy Consultant | Whistleblower Attorney | Fmr. Sr. Advisor & Counselor to the New York Attorney General | Fmr. Director of the New York Senate Policy Group & Special Counsel. Adj. Law professor (2015-2023).
2moFun fact: the very first Department of Justice anti-trust suit in health care, in the 1940s, was against price collusion in the manufacturing of insulin.